Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955156 | 0.86 | LMNA (0.48) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| SCHEMBL12934601 | 0.86 | RIPK1 (0.57) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| SCHEMBL24160987 | 0.84 | CHRNA7 (0.48) | TDP1NAPRTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4665006 | 0.84 | CYP17A1 (0.46) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| SCHEMBL4665010 | 0.84 | CYP17A1 (0.46) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| SCHEMBL4664410 | 0.84 | CYP17A1 (0.46) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| Hydrochloric Acid SCHEMBL4667959 | 0.83 | CYP17A1 (0.45) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| Hydrochloric Acid SCHEMBL4666403 | 0.83 | CYP17A1 (0.45) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| Hydrochloric Acid SCHEMBL4666399 | 0.83 | CYP17A1 (0.45) | KMT2ALMNATDP1CYP17A1CYP19A1 | |
| SCHEMBL10812367 | 0.82 | TBXAS1 (0.49) | KMT2ALMNATDP1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-1867650-B1 | HYDROXYMETHYLBORON COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1867650-B1 | HYDROXYMETHYLBORON COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7696347-B2 | Oxymethyl boron compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-7696347-B2 | Oxymethyl boron compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-7696347-B2 | Oxymethyl boron compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1867650-A1 | HYDROXYMETHYLBORON COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867650-A1 | HYDROXYMETHYLBORON COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242859-A1 | Oxymethyl Boron Compounds | BPGM, DDT, DBN1 | KMT2A 228/4885LMNA 4472/4885TDP1 2090/4885 |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | SIRT1, NQO1, TXNRD2 | KMT2A 121/4885LMNA 2553/4885TDP1 1260/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KMT2A 3464/4885LMNA 1748/4885TDP1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.